Conscious Beauty, launching at Ulta in the fall, is built around five pillars for product certification – clean ingredients, cruelty free, vegan, sustainable packaging and positive impact. Clean ingredients means no parabens, phthalates or listed ingredients in 25 other categories, the retailer says.

Public Company Edition: June has seen 14 initial public offerings by drug developers (and one big biopharma funder) after there were only 15 from January through May – and the month isn’t over yet. Follow-on and other offerings also are hitting the market at a rapid pace.

Takeda has won EU approval for an injectable version of Entyvio to treat ulcerative colitis or Crohn’s disease, in contrast to the FDA’s rejection in December.

While COVID-19 shocked global financial markets and is expected to impact biopharma fundraising, investment in drug developers continues, including through two new venture capital funds totaling nearly $2bn. Also, Coherus issues debt to fund deals and MOMA launches with $86m in VC cash.